Adaptimmune Therapeutics Intrinsic Value – Adaptimmune Therapeutics Reports 14-Cent EPS Beat on $47.6M Revenue

Trending News 🌥️

The company exceeded expectations by achieving a GAAP earnings per share of $0.14 and total revenue of $47.6 million. The company’s strong performance was largely driven by its core therapy, which is focused on treating solid and hematologic cancers. The therapy has been shown to generate durable responses in late-stage cancer patients, and the company is continuing to expand its addressable market. As a result, Adaptimmune ($NASDAQ:ADAP) has been successful in expanding its customer base and improving its top-line results.

In terms of product pipeline, the company is making significant progress in the development of novel therapies, which promises to further enhance its financial results in the coming quarters. Looking ahead, Adaptimmune’s strong financial performance is expected to continue as the company continues to gain traction in the healthcare industry and further expands its addressable market with its innovative therapies.

Earnings

In its earnings report of FY2022 Q4 as of December 31 2022, ADAPTIMMUNE THERAPEUTICS reported a total revenue of 11.03M USD and a net income loss of 29.25M USD. This marks a 676.8% increase in total revenue compared to the same period the previous year. In the last 3 years, ADAPTIMMUNE THERAPEUTICS has seen their total revenue grow from 1.5M USD to 11.03M USD.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Adaptimmune Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Adaptimmune Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Adaptimmune Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Adaptimmune Therapeutics are shown below. More…

Price History

On Friday, Adaptimmune Therapeutics reported that it beat revenue expectations for the fourth quarter, with revenue totaling $47.6M. Following the announcement, Adaptimmune Therapeutics’ stock opened at $1.4 and closed at the same price, up by 0.7% from the previous closing. Live Quote…

Analysis – Adaptimmune Therapeutics Intrinsic Value

At GoodWhale, we have conducted an in-depth analysis of ADAPTIMMUNE THERAPEUTICS‘ wellbeing and have determined that their intrinsic value is around $19.5, as calculated by our proprietary Valuation Line. This value is determined by taking into account a variety of factors, such as current and past stock prices, industry trends, and financial health. However, at the time of writing, ADAPTIMMUNE THERAPEUTICS’ stock is currently trading at $1.4. This represents a substantial undervaluation of the stock, with a difference of 92.8%. In other words, the current share price does not accurately reflect the intrinsic value of the company. We believe that the stock is a worthy investment for those looking for strong returns in the future. More…

Peers

The company’s T-cell therapy platform harnesses the body’s own immune system to target and kill cancer cells. Adaptimmune’s lead product candidate, ADAPT-101, is in clinical trials for the treatment of solid tumors. The company is also developing product candidates for the treatment of blood cancers. Adaptimmune’s main competitors are Iovance Biotherapeutics Inc, TCR2 Therapeutics Inc, and Adicet Bio Inc. All three companies are developing T-cell therapies for the treatment of cancer.

– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

Iovance Biotherapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of cancer immunotherapy products. The company has a market cap of 1.24B as of 2022 and a Return on Equity of -56.45%. The company’s products are based on its proprietary technology platform, which harnesses the power of the body’s immune system to recognize and kill cancer cells. Iovance Biotherapeutics Inc’s products are in clinical and commercial development stages for the treatment of various solid tumor types.

– TCR2 Therapeutics Inc ($NASDAQ:TCRR)

The company’s market cap is 49.48 million as of 2022, a return on equity of -24.78%. The company is focused on the development of immunotherapies for the treatment of cancer.

– Adicet Bio Inc ($NASDAQ:ACET)

Adicet Bio Inc is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.

Adicet Bio Inc has a market cap of 836.46M as of 2022, a Return on Equity of -9.85%. Adicet Bio is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.

Summary

Investors have responded positively to the news, as the stock price has increased following the announcement. In addition to the positive financial performance, Adaptimmune has announced plans to expand its pipeline of therapies and clinical trials to offer more treatments for different types of cancer. The company is investing in research and development to further advance its products and is confident in its future prospects. Therefore, investors should consider monitoring Adaptimmune’s latest developments and financial performance to determine if it is a worthwhile investment.